These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27586794)

  • 61. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
    Jackson RJ; Worley M; Trivedi S; Ranasinghe C
    Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term presence of memory B-cells specific for different vaccine components.
    Buisman AM; de Rond CG; Oztürk K; Ten Hulscher HI; van Binnendijk RS
    Vaccine; 2009 Dec; 28(1):179-86. PubMed ID: 19799844
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Migration, maintenance and recall of memory T cells in peripheral tissues.
    Woodland DL; Kohlmeier JE
    Nat Rev Immunol; 2009 Mar; 9(3):153-61. PubMed ID: 19240755
    [TBL] [Abstract][Full Text] [Related]  

  • 64. T Cell Memory in Infection, Cancer, and Autoimmunity.
    Barnaba V
    Front Immunol; 2021; 12():811968. PubMed ID: 35069600
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Maintenance of Memory Plasma Cells.
    Khodadadi L; Cheng Q; Radbruch A; Hiepe F
    Front Immunol; 2019; 10():721. PubMed ID: 31024553
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of regulatory B cells in digestive system diseases.
    Zhou Z; Gong L; Wang X; Hu Z; Wu G; Tang X; Peng X; Tang S; Meng M; Feng H
    Inflamm Res; 2017 Apr; 66(4):303-309. PubMed ID: 27878329
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The basics and advances of immunomodulators and antigen presentation: a key to development of potent memory response against pathogens.
    Garai P; Gogoi M; Gopal G; Radhakrishnan Y; Nandakumar KS; Chakravortty D
    Expert Opin Biol Ther; 2014 Oct; 14(10):1383-97. PubMed ID: 24897303
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predicting vaccine responsiveness.
    Boyd SD; Jackson KJL
    Cell Host Microbe; 2015 Mar; 17(3):301-307. PubMed ID: 25766292
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antibody-based vaccine strategies against intracellular pathogens.
    Casadevall A
    Curr Opin Immunol; 2018 Aug; 53():74-80. PubMed ID: 29704764
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Regulatory B Cells: Dark Horse in Pregnancy Immunotherapy?
    Guzman-Genuino RM; Hayball JD; Diener KR
    J Mol Biol; 2021 Jan; 433(1):166596. PubMed ID: 32693108
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Editorial: Immunotherapeutic and Immunoprophylactic Strategies for Infectious Diseases.
    Sautto GA; Diotti RA
    Front Immunol; 2020; 11():1670. PubMed ID: 32849578
    [No Abstract]   [Full Text] [Related]  

  • 72. [Immunologic foundations of new vaccination strategies].
    Kaufmann SH
    Naturwissenschaften; 1998 Feb; 85(2):62-72. PubMed ID: 9530641
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations.
    Sanz I; Wei C; Jenks SA; Cashman KS; Tipton C; Woodruff MC; Hom J; Lee FE
    Front Immunol; 2019; 10():2458. PubMed ID: 31681331
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epidemiological determinants of successful vaccine development.
    Nishiura H; Mizumoto K
    Int J Med Sci; 2013; 10(4):382-4. PubMed ID: 23471119
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers.
    Buchwald UK; Pirofski L
    Curr Pharm Des; 2003; 9(12):945-68. PubMed ID: 12678861
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Improving Vaccine and Immunotherapy Design Using Biomaterials.
    Bookstaver ML; Tsai SJ; Bromberg JS; Jewell CM
    Trends Immunol; 2018 Feb; 39(2):135-150. PubMed ID: 29249461
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents.
    Reina-San-Martin B; Cosson A; Minoprio P
    Parasitol Today; 2000 Feb; 16(2):62-7. PubMed ID: 10652489
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Formulation technologies for oral vaccines.
    New RRC
    Clin Exp Immunol; 2019 Nov; 198(2):153-169. PubMed ID: 31318446
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Innovative Approaches to Improve Anti-Infective Vaccine Efficacy.
    Yeaman MR; Hennessey JP
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():189-222. PubMed ID: 28061685
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Letter from the Editor.
    Hum Vaccin Immunother; 2018 Jan; 14(1):1. PubMed ID: 29324170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.